Clasado Biosciences has outlined the potential growth ahead of the functional gummy sector, along with the exciting potential for prebiotics in this product segment.
Reflecting the category’s robust projected compound annual growth rate of 10.2% to 2027 according to intelligence firm Ameco Research, Clasado has observed a significant increase in global demand for gummy supplements and sees strong commercial potential for prebiotic gummies.
David Mharakurwa, Director of Sales APAC & MEA at Clasado Biosciences, explains: “In conversation with our customers, we are seeing functional gummies becoming a much more common sight in the global market, with Europe and North America being particularly pronounced. Consumer demand is clearly there, and with gummy formats able to command a price premium over capsule and tablet counterparts in markets such as Europe and Asia, formulators in the health and nutrition space are certainly taking notice.
“In terms of what’s driving this growth, one strong possibility is the surging overall interest in health and wellbeing on the back of the Covid-19 pandemic. As consumers, we have a changing relationship with what it means to be healthy and, for many of us, that means carrying out simple everyday actions as ‘preventive maintenance’ for the body. Gummies fit this role perfectly, so it’s easy to see why they’re gathering such momentum.
“We have seen vitamin gummies growing for some time becoming an established market segment, but what’s next? It’s clear that prebiotics, probiotics and fibre are set to dominate the conversation in new functional gummy development, particularly with the rapid advance and awareness of gut health science.”
Clasado is the developer and manufacturer of the multi award-winning Bimuno® GOS, a prebiotic galactooligosaccharide (GOS) ingredient designed to add real value for formulators. The stable and versatile prebiotic fibre is the most studied of its kind, supported by over 100 scientific publications, including more than 20 clinical trials.
The business is delivering an ambitious global expansion strategy, bringing its pioneering prebiotic ingredient to partners and distributors in Europe, North America, Asia, EMEA, Australia and New Zealand.
David added: “There’s strong commercial opportunity right here and right now. As well as standalone products, for formulators already developing their vitamin and mineral gummies, prebiotic ingredients such as Bimuno are a way to instantly uplift formulations and provide a stronger complete nutritional profile. In fact, Bimuno is ideal for this application thanks to its extremely low effective dose of just 1.8 grams.
“The gummy market is clearly moving from strength to strength and it’s a pattern being seen across the globe. Looking towards the next step in the format’s evolution, we are expecting to see gummies pivot towards more targeted and specific health applications, in areas such as immune defence, gut health and cognition.”
To find out more about Clasado Biosciences, please visit www.clasado.com
